Drug intelligence / Profile preview

TCellMune-RD

Development stage: Preclinical
Lead developer: Vaxxit
Modality: Vaccines & Immunotherapeutics

Overview

TCellMune-RD is a replication-defective herpes simplex virus (HSV) vaccine candidate developed by Vaxxit for the prevention and treatment of HSV-1 and HSV-2 infections. The vaccine is engineered to be unable to replicate in human cells, providing a safety profile while effectively presenting viral antigens to stimulate a robust T-cell immune response. By targeting both HSV-1 and HSV-2, TCellMune-RD aims to address the broad clinical manifestations of herpes infections. It is currently in preclinical development.

Other names: TCellMune RD

Beyond the preview

Go deeper on TCellMune-RD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCellMune-RD.

Explore the full profile